PMID- 31348306
OWN - NLM
STAT- MEDLINE
DCOM- 20190813
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 30
DP  - 2019 Jul
TI  - Evaluation of hippocampal volume and serum brain-derived neurotrophic factor as 
      potential diagnostic markers of conversion from amnestic mild cognitive 
      impairment to Alzheimer disease: A STROBE-compliant article.
PG  - e16604
LID - 10.1097/MD.0000000000016604 [doi]
LID - e16604
AB  - Amnestic mild cognitive impairment (aMCI) is a transitional stage between normal 
      aging and Alzheimer disease (AD), and is associated with an increased risk of AD. 
      Many studies have shown that apolipoprotein E epsilon 4 (APOE epsilon4) genotype is a 
      major genetic predictor of AD progression, especially in patients with aMCI. 
      However, the application of APOE genotyping in the diagnosis of MCI progressing 
      to AD is limited by its low sensitivity and specificity, which often leads to 
      high false-positive rate. The aim of this study was to evaluate serum 
      brain-derived neurotrophic factor (BDNF) and hippocampal volume as predictors of 
      aMCI to AD transition in APOE epsilon4 genotype patients.A total of 178 subjects were 
      diagnosed with aMCI. The patients with aMCI that progressed to AD within 2 years 
      were included in the MCI-AD group (n = 86), those maintaining an aMCI diagnosis 
      after 2 years were placed in the MCI-MCI group (n = 92), and neurologically 
      healthy age-matched individuals were set as controls (n = 90). APOE genotypes 
      were determined. Blood samples from all subjects were drawn at baseline, 12 
      months, and 24 months for serum BNDF assessments. Hippocampal delineations were 
      monitored by magnetic resonance imaging.Compared to control group, aMCI-AD 
      patients (the patients with aMCI that progressed to AD within 2 years) exhibited 
      worse performance on cognitive and neuropsychological batteries. Meanwhile, we 
      found that aMCI-AD patients were associated with abnormally low serum BDNF level 
      and greater hippocampal volume loss than MCI-MCI patients (patients maintaining 
      an aMCI diagnosis after 2 years). Moreover, patients with aMCI who were carriers 
      of APOE epsilon4 showed a notable decrease in serum BDNF and a significant reduction in 
      hippocampal volume, especially in those who progressed to AD.The present study 
      demonstrates that aMCI that evolves into AD in patients with the APOE epsilon4 genotype 
      may be predicted by hippocampal volume and serum BDNF.
FAU - Fang, Yan
AU  - Fang Y
AD  - Medical Affair Department.
FAU - Du, Naiyi
AU  - Du N
AD  - Department of Magnetic Resonance Imaging.
FAU - Xing, Longyan
AU  - Xing L
AD  - Department of Magnetic Resonance Imaging.
FAU - Duo, Yali
AU  - Duo Y
AD  - Central Laboratory, Harrison International Peace Hospital, Hengshui, Hebei, 
      China.
FAU - Zheng, Lei
AU  - Zheng L
AD  - Central Laboratory, Harrison International Peace Hospital, Hengshui, Hebei, 
      China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (ApoE protein, human)
RN  - 0 (Apolipoproteins E)
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*diagnosis/genetics
MH  - Apolipoproteins E/*genetics
MH  - Biomarkers
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cognitive Dysfunction/*diagnosis/genetics
MH  - Female
MH  - Hippocampus/*anatomy & histology
MH  - Humans
MH  - Male
MH  - Mental Status and Dementia Tests
MH  - Middle Aged
PMC - PMC6709245
COIS- The authors report no conflicts of interest.
EDAT- 2019/07/28 06:00
MHDA- 2019/08/14 06:00
PMCR- 2019/07/26
CRDT- 2019/07/27 06:00
PHST- 2019/07/27 06:00 [entrez]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2019/07/26 00:00 [pmc-release]
AID - 00005792-201907260-00081 [pii]
AID - MD-D-19-00545 [pii]
AID - 10.1097/MD.0000000000016604 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Jul;98(30):e16604. doi: 10.1097/MD.0000000000016604.